A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Trial details
- Registry ID
- NCT02656303
- Phase
- Phase 2
The FDA approved Ublituximab (BRIUMVI) on 28 Dec 2022.
Drug identity checked against registry records
Also recorded as BRIUMVI; TG-1101
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-12-28Day | UblituximabTG Therapeutics, Inc. · TGTX | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761238", "applicant_as_listed_by_fda": "TG THERAPEUTICS, INC", "brand_names": ["BRIUMVI"], "active_ingredients": ["UBLITUXIMAB-XIIY"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |